{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T11:21:24Z","timestamp":1793532084482,"version":"4.5.0"},"reference-count":86,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.ijantimicag.2023.106942","type":"journal-article","created":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T06:10:15Z","timestamp":1691043015000},"page":"106942","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Macrolides for better resolution of community-acquired pneumonia: A global meta-analysis of clinical outcomes with focus on microbial aetiology"],"prefix":"10.1016","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1260-1789","authenticated-orcid":false,"given":"Miltiades","family":"Kyprianou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7399-4884","authenticated-orcid":false,"given":"Konstantina","family":"Dakou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aftab","family":"Aktar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hichem","family":"Aouina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naser","family":"Behbehani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keertan","family":"Dheda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges","family":"Juvelekian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adel","family":"Khattab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassam","family":"Mahboub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7929-7269","authenticated-orcid":false,"given":"George","family":"Nyale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayed","family":"Oraby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6788-9727","authenticated-orcid":false,"given":"Abdullah","family":"Sayiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atef","family":"Shibl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Awad Tag","family":"El Deen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serhat","family":"Unal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Bin Sarwar","family":"Zubairi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5361-0038","authenticated-orcid":false,"given":"Ross","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4713-3911","authenticated-orcid":false,"given":"Evangelos J.","family":"Giamarellos-Bourboulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2023.106942_bib0001","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","article-title":"Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America","volume":"200","author":"Metlay","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0002","unstructured":"British Thoracic Society. Annotated BTS guideline for the management of CAP in adults. https:\/\/www.brit-thoracic.org.uk\/quality-improvement\/guidelines\/pneumonia-adults (accessed 4 July 2023)."},{"issue":"Suppl 6","key":"10.1016\/j.ijantimicag.2023.106942_bib0003","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1111\/j.1469-0691.2011.03672.x","article-title":"Guidelines for the management of adult lower respiratory tract infections","volume":"17","author":"Woodhead","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0004","unstructured":"National Institute for Health and Care Excellence. Pneumonia (community-acquired): antimicrobial prescribing. https:\/\/www.nice.org.uk\/guidance\/ng138 (accessed 4 July 2023)."},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0005","doi-asserted-by":"crossref","first-page":"105836","DOI":"10.1016\/j.ijantimicag.2019.10.017","article-title":"Survival benefit associated with clarithromycin in severe community-acquired pneumonia: a matched comparator study","volume":"55","author":"Kyriazopoulou","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0006","doi-asserted-by":"crossref","first-page":"94","DOI":"10.5578\/tt.9110","article-title":"Comparison of ampicillin-sulbactam\/macrolide dual therapy versus fluoroquinolone monotherapy in hospitalized patients with community-acquired pneumonia","volume":"63","author":"Karabo\u011fa","year":"2015","journal-title":"Tuberk Toraks"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0007","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1001\/jamainternmed.2014.4887","article-title":"\u03b2-Lactam monotherapy vs \u03b2-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial","volume":"174","author":"Garin","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0008","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1093\/jac\/dkp088","article-title":"Impact of intravenous {beta}-lactam\/macrolide versus {beta}-lactam monotherapy on mortality in patients with community-acquired pneumonia","volume":"63","author":"Tessmer","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0009","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00151829-200403050-00006","article-title":"Comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with step-down oral therapy for hospitalized patients with moderate to severe community-acquired pneumonia","volume":"3","author":"Zervos","year":"2004","journal-title":"Treat Respir Med"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0010","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/BF01973989","article-title":"Penicillin G\/ofloxacin versus erythromycin\/amoxicillin-clavulanate in the treatment of severe community-acquired pneumonia","volume":"13","author":"Gaillat","year":"1994","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0011","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.chest.2018.11.006","article-title":"Effect of combined \u03b2-lactam\/macrolide therapy on mortality according to the microbial etiology and inflammatory status of patients with community-acquired pneumonia","volume":"155","author":"Ceccato","year":"2019","journal-title":"Chest"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0012","first-page":"6","article-title":"Beta-lactam plus macrolide vs fluoroquinolone for empiric therapy of hospitalized patients with CAP: results from the University of Louisville Pneumonia Study","volume":"3","author":"Salunkhe","year":"2019","journal-title":"J Resp Infect"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0013","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/resp.13232","article-title":"Mortality in patients with community-onset pneumonia at low risk of drug-resistant pathogens: impact of \u03b2-lactam plus macrolide combination therapy","volume":"23","author":"Okumura","year":"2018","journal-title":"Respirology"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0014","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.rmed.2018.05.020","article-title":"Macrolide therapy is associated with lower mortality in community-acquired bacteraemic pneumonia","volume":"140","author":"Arnold","year":"2018","journal-title":"Respir Med"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0015","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1136\/thoraxjnl-2012-202296","article-title":"Single versus combination antibiotic therapy in adults hospitalised with community acquired pneumonia","volume":"68","author":"Rodrigo","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0016","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/thoraxjnl-2012-203106","article-title":"Contribution of host, bacterial factors and antibiotic treatment to mortality in adult patients with bacteraemic pneumococcal pneumonia","volume":"68","author":"Naucler","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0017","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/aas.12081","article-title":"Severe community-acquired pneumonia treated with \u03b2-lactam-respiratory quinolone vs. \u03b2-lactam-macrolide combination","volume":"57","author":"Karhu","year":"2013","journal-title":"Acta Anaesthesiol Scand"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0018","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1097\/CCM.0b013e31825151a8","article-title":"Comparison of two guideline-concordant antimicrobial combinations in elderly patients hospitalized with severe community-acquired pneumonia","volume":"40","author":"Wilson","year":"2012","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0019","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1183\/09031936.00054108","article-title":"Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia","volume":"33","author":"Restrepo","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0020","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1086\/586749","article-title":"The etiology of community-acquired pneumonia in Australia: why penicillin plus doxycycline or a macrolide is the most appropriate therapy","volume":"46","author":"Charles","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0021","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1086\/591404","article-title":"Initial antibiotic selection and patient outcomes: observations from the National Pneumonia Project","volume":"47","author":"Bratzler","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0022","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.rmed.2007.04.018","article-title":"Empiric treatment in hospitalized community-acquired pneumonia. Impact on mortality, length of stay and re-admission","volume":"101","author":"Reyes Calzada","year":"2007","journal-title":"Respir Med"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0023","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1183\/09031936.00031007","article-title":"The need for macrolides in hospitalised community-acquired pneumonia: propensity analysis","volume":"30","author":"Paul","year":"2007","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0024","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1378\/chest.06-1426","article-title":"Antibiotics for bacteremic pneumonia: improved outcomes with macrolides but not fluoroquinolones","volume":"131","author":"Metersky","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0025","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1128\/AAC.00006-07","article-title":"Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia","volume":"51","author":"Lodise","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0026","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/s10096-006-0183-2","article-title":"Addition of a macrolide to a ss-lactam in bacteremic pneumococcal pneumonia","volume":"25","author":"Dwyer","year":"2006","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0027","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1183\/09031936.06.00126004","article-title":"Impact of initial antibiotic choice on mortality from pneumococcal pneumonia","volume":"27","author":"Aspa","year":"2006","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0028","doi-asserted-by":"crossref","first-page":"R8","DOI":"10.1186\/cc3934","article-title":"The impact of empiric antimicrobial therapy with a \u03b2-lactam and fluoroquinolone on mortality for patients hospitalized with severe pneumonia","volume":"10","author":"Mortensen","year":"2005","journal-title":"Crit Care"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0029","first-page":"589","article-title":"Clinical characteristics at initial presentation and impact of dual therapy on the outcome of bacteremic Streptococcus pneumoniae pneumonia in adults","volume":"11","author":"Weiss","year":"2004","journal-title":"Can Respir J"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0030","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ijantimicag.2004.07.013","article-title":"Levofloxacin versus ceftriaxone plus clarithromycin in the treatment of adults with community-acquired pneumonia requiring hospitalization","volume":"25","author":"Querol-Ribelles","year":"2005","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0031","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1592\/phco.23.10.1167.32764","article-title":"Impact of atypical coverage for patients with community-acquired pneumonia managed on the medical ward: results from the United States community-acquired pneumonia project","volume":"23","author":"Frei","year":"2003","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0032","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1378\/chest.123.5.1503","article-title":"Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database","volume":"123","author":"Brown","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0033","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1007\/s00134-002-1325-3","article-title":"Associations between empirical antimicrobial therapy at the hospital and mortality in patients with severe community-acquired pneumonia","volume":"28","author":"Rello","year":"2002","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0034","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S0149-2918(00)80059-4","article-title":"Effect of macrolides as part of initial empiric therapy on medical outcomes for hospitalized patients with community-acquired pneumonia","volume":"22","author":"Burgess","year":"2000","journal-title":"Clin Ther"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0035","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1001\/archinte.159.21.2562","article-title":"Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia","volume":"159","author":"Gleason","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0036","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.2147\/IDR.S182777","article-title":"Community acquired pneumonia among adult patients at an Egyptian university hospital: bacterial etiology, susceptibility profile and evaluation of the response to initial empiric antibiotic therapy","volume":"11","author":"El-Sokkary","year":"2018","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0037","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1179\/joc.2005.17.6.636","article-title":"Clinical efficacy and safety of a short regimen of azithromycin sequential therapy vs standard cefuroxime sequential therapy in the treatment of community-acquired pneumonia: an international, randomized, open-label study","volume":"17","author":"Kuzman","year":"2005","journal-title":"J Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0038","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jemermed.2004.02.023","article-title":"Safety and efficacy of sequential i.v. to p.o. moxifloxacin versus conventional combination therapies for the treatment of community-acquired pneumonia in patients requiring initial i.v. therapy","volume":"27","author":"Katz","year":"2004","journal-title":"J Emerg Med"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0039","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/S0149-2918(02)85148-7","article-title":"A controlled, double-blind, multicenter study comparing clarithromycin extended-release tablets and levofloxacin tablets in the treatment of community-acquired pneumonia","volume":"24","author":"Gotfried","year":"2002","journal-title":"Clin Ther"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0040","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1053\/rmed.2001.1113","article-title":"The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia","volume":"95","author":"Hoeffken","year":"2001","journal-title":"Respir Med"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0041","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0149-2918(00)88271-5","article-title":"Sparfloxacin versus clarithromycin in the treatment of community-acquired pneumonia","volume":"21","author":"Ramirez","year":"1999","journal-title":"Clin Ther"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0042","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1378\/chest.116.4.974","article-title":"A multicenter study of grepafloxacin and clarithromycin in the treatment of patients with community-acquired pneumonia","volume":"116","author":"Moola","year":"1999","journal-title":"Chest"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0043","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/BF01700406","article-title":"Clarithromycin versus amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia","volume":"16","author":"Genn\u00e9","year":"1997","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0044","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1183\/09031936.95.08121999","article-title":"Treatment of community-acquired pneumonia: a randomized comparison of sparfloxacin, amoxycillin-clavulanic acid and erythromycin","volume":"8","author":"Lode","year":"1995","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0045","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/BF02310353","article-title":"Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community-acquired pneumonia","volume":"14","author":"Bohte","year":"1995","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0046","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.13667","article-title":"Aetiology and antimicrobial susceptibility pattern of bacterial isolates in community acquired pneumonia patients at Asir region, Saudi Arabia","volume":"75","author":"Batool","year":"2021","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0047","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/crj.13137","article-title":"Factors predicting in-hospital mortality among patients admitted with community acquired pneumonia at a tertiary care hospital Karachi, Pakistan","volume":"14","author":"Iqbal","year":"2020","journal-title":"Clin Respir J"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0048","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.4314\/ahs.v20i4.18","article-title":"Clinical and microbiological profile of adult inpatients with community acquired pneumonia in Ilorin, North Central, Nigeria","volume":"20","author":"Ojuawo","year":"2020","journal-title":"Afr Health Sci"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0049","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ijid.2018.02.008","article-title":"Proportion of adult community-acquired pneumonia cases attributable to Streptococcus pneumoniae among Hajj pilgrims in 2016","volume":"69","author":"AlBarrak","year":"2018","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0050","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3923\/pjbs.2018.409.413","article-title":"Risk factors and microbiological studies on Streptococcus pneumoniae isolated from pneumonia patients of Quetta Balochistan","volume":"21","author":"Baloch","year":"2018","journal-title":"Pak J Biol Sci"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0051","doi-asserted-by":"crossref","DOI":"10.5812\/jjm.22780","article-title":"Etiological diagnosis of community-acquired pneumonia in adult patients: a prospective hospital-based study in Mashhad, Iran","volume":"8","author":"Naderi","year":"2015","journal-title":"Jundishapur J Microbiol"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0052","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.3201\/eid2011.140600","article-title":"Respiratory viruses and bacteria among pilgrims during the 2013 Hajj","volume":"20","author":"Benkouiten","year":"2014","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0053","doi-asserted-by":"crossref","first-page":"875","DOI":"10.3109\/00365548.2014.954263","article-title":"Sputum bacteriology and antibiotic sensitivity patterns of community-acquired pneumonia in hospitalized adult patients in Nigeria: a 5-year multicentre retrospective study","volume":"46","author":"Iroezindu","year":"2014","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0054","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/1471-2466-14-105","article-title":"Efficacy and safety of moxifloxacin in community acquired pneumonia: a prospective, multicenter, observational study (CAPRIVI)","volume":"14","author":"Kuzman","year":"2014","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0055","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1465-9921-14-44","article-title":"Current management of patients hospitalized with community-acquired pneumonia across Europe: outcomes from REACH","volume":"14","author":"Blasi","year":"2013","journal-title":"Respir Res"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0056","first-page":"91","article-title":"A prospective study of inpatients to determine microbial etiology and therapeutic outcome of antibiotics for community-acquired pneumonia in Pakistan","volume":"3","author":"Rehman","year":"2013","journal-title":"Bioimpacts"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0057","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1503\/cmaj.080358","article-title":"Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials","volume":"179","author":"Vardakas","year":"2008","journal-title":"CMAJ"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0058","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/cid\/cis414","article-title":"Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis","volume":"55","author":"Asadi","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0059","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/CCM.0b013e3182a66b9b","article-title":"Macrolides and mortality in critically ill patients with community-acquired pneumonia: a systematic review and meta-analysis","volume":"42","author":"Sligl","year":"2014","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0060","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1093\/jac\/dku033","article-title":"\u03b2-Lactam\/macrolide dual therapy versus \u03b2-lactam monotherapy for the treatment of community-acquired pneumonia in adults: a systematic review and meta-analysis","volume":"69","author":"Nie","year":"2014","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.ijantimicag.2023.106942_bib0061","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ijantimicag.2015.04.010","article-title":"Fluoroquinolones or macrolides alone versus combined with \u03b2-lactams for adults with community-acquired pneumonia: systematic review and meta-analysis","volume":"46","author":"Raz-Pasteur","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0062","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1111\/resp.12835","article-title":"Beta-lactam plus macrolides or beta-lactam alone for community-acquired pneumonia: a systematic review and meta-analysis","volume":"21","author":"Horita","year":"2016","journal-title":"Respirology"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0063","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3346\/jkms.2017.32.1.77","article-title":"Is \u03b2-Lactam plus macrolide more effective than \u03b2-lactam plus fluoroquinolone among patients with severe community-acquired pneumonia?: a systemic review and meta-analysis","volume":"32","author":"Lee","year":"2017","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0064","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.cmi.2016.12.002","article-title":"Fluoroquinolones or macrolides in combination with \u03b2-lactams in adult patients hospitalized with community acquired pneumonia: a systematic review and meta-analysis","volume":"23","author":"Vardakas","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0065","first-page":"47","article-title":"The dilemma of monotherapy or combination therapy in community-acquired pneumonia","author":"Vardakas","year":"2017","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0066","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.pharmthera.2014.03.003","article-title":"Azithromycin: mechanisms of action and their relevance for clinical applications","volume":"143","author":"Parnham","year":"2014","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0067","doi-asserted-by":"crossref","first-page":"ofab063","DOI":"10.1093\/ofid\/ofab063","article-title":"A multicenter evaluation of the US prevalence and regional variation in macrolide-resistant S. pneumoniae in ambulatory and hospitalized adult patients in the United States","volume":"8","author":"Gupta","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0068","doi-asserted-by":"crossref","first-page":"e379","DOI":"10.1016\/S1473-3099(18)30414-6","article-title":"Epidemiology of common resistant bacterial pathogens in the countries of the Arab league","volume":"18","author":"Moghnieh","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0069","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1099\/mic.0.040618-0","article-title":"Long-term impacts of antibiotic exposure on the human intestinal microbiota","volume":"156","author":"Jernberg","year":"2010","journal-title":"Microbiology"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0070","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/ismej.2007.3","article-title":"Long-term ecological impacts of antibiotic administration on the human intestinal microbiota","volume":"1","author":"Jernberg","year":"2007","journal-title":"ISME J"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0071","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/S0140-6736(07)60235-9","article-title":"Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study","volume":"369","author":"Malhotra-Kumar","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0072","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1093\/jac\/dkg138","article-title":"Comparative distribution of azithromycin in lung tissue of patients given oral daily doses of 500 and 1000 mg","volume":"51","author":"Danesi","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0073","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1093\/jac\/dkg355","article-title":"Steady-state plasma and bronchopulmonary characteristics of clarithromycin extended-release tablets in normal healthy adult subjects","volume":"53","author":"Gotfried","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0074","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1086\/529439","article-title":"Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia","volume":"46","author":"Giamarellos-Bourboulis","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0075","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1093\/jac\/dkt475","article-title":"Effect of clarithromycin in patients with suspected Gram-negative sepsis: results of a randomized controlled trial","volume":"69","author":"Giamarellos-Bourboulis","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0076","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s13054-022-04055-4","article-title":"Effect of intravenous clarithromycin in patients with sepsis, respiratory and multiple organ dysfunction syndrome: a randomized clinical trial","volume":"26","author":"Karakike","year":"2022","journal-title":"Crit Care"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0077","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1128\/AAC.02974-15","article-title":"Clarithromycin leads to long-term survival and cost benefit in ventilator-associated pneumonia and sepsis","volume":"60","author":"Tsaganos","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0078","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1128\/AAC.05798-11","article-title":"Effect of clarithromycin in inflammatory markers of patients with ventilator-associated pneumonia and sepsis caused by Gram-negative bacteria: results from a randomized clinical study","volume":"56","author":"Spyridaki","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0079","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1093\/cid\/ciac317","article-title":"The effect of macrolides on mortality in bacteremic pneumococcal pneumonia: a retrospective, nationwide cohort study, Israel, 2009\u20132017","volume":"75","author":"Chowers","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0080","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1500245","article-title":"Community-acquired pneumonia requiring hospitalization among US adults","volume":"373","author":"Jain","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0081","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1007\/s40121-021-00459-x","article-title":"BioFire\u00aeFilmArray\u00ae pneumonia panel for severe lower respiratory tract infections: subgroup analysis of a randomized clinical trial","volume":"10","author":"Kyriazopoulou","year":"2021","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0082","doi-asserted-by":"crossref","DOI":"10.1177\/1179548419862790","article-title":"Streptococcus pneumoniae as a cause of community-acquired pneumonia in Indian adolescents and adults: a systematic review and meta-analysis","volume":"13","author":"Ghia","year":"2019","journal-title":"Clin Med Insights Circ Respir Pulm Med"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0083","series-title":"Guidance for industry; community-acquired bacterial pneumonia: developing drugs for treatment guidance for industry","year":"2020"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0084","doi-asserted-by":"crossref","first-page":"e2607","DOI":"10.1093\/cid\/ciaa860","article-title":"Concordance of early and late end points for community-acquired bacterial pneumonia trials","volume":"73","author":"Bart","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0085","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1473-3099(16)00017-7","article-title":"Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL)","volume":"16","author":"Barrera","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106942_bib0086","unstructured":"Anti-inflammatory action of oral clarithromycin in community-acquired pneumonia (ACCESS). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04724044 (accessed 4 July 2023)."}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857923002212?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857923002212?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:47:26Z","timestamp":1760377646000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857923002212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":86,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S0924857923002212"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106942","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Macrolides for better resolution of community-acquired pneumonia: A global meta-analysis of clinical outcomes with focus on microbial aetiology","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106942","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106942"}}